Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences (RNA) Accumulated Expenses: 2019-2024

Historic Accumulated Expenses for Avidity Biosciences (RNA) over the last 6 years, with Dec 2024 value amounting to $64.7 million.

  • Avidity Biosciences' Accumulated Expenses rose 651.95% to $137.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $137.2 million, marking a year-over-year increase of 651.95%. This contributed to the annual value of $64.7 million for FY2024, which is 351.52% up from last year.
  • Avidity Biosciences' Accumulated Expenses amounted to $64.7 million in FY2024, which was up 351.52% from $14.3 million recorded in FY2023.
  • Over the past 5 years, Avidity Biosciences' Accumulated Expenses peaked at $64.7 million during FY2024, and registered a low of $3.2 million during FY2020.
  • Moreover, its 3-year median value for Accumulated Expenses was $14.3 million (2023), whereas its average is $30.1 million.
  • Data for Avidity Biosciences' Accumulated Expenses shows a peak YoY spiked of 351.52% (in 2024) over the last 5 years.
  • Over the past 5 years, Avidity Biosciences' Accumulated Expenses (Yearly) stood at $3.2 million in 2020, then spiked by 183.63% to $8.9 million in 2021, then rose by 25.17% to $11.2 million in 2022, then increased by 28.11% to $14.3 million in 2023, then soared by 351.52% to $64.7 million in 2024.